메뉴 건너뛰기




Volumn 65, Issue 6, 2011, Pages 713-715

Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: A retrospective cohort study

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CREATINE KINASE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RIMONABANT; TRIACYLGLYCEROL;

EID: 79956106203     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02683.x     Document Type: Letter
Times cited : (14)

References (9)
  • 1
    • 33751019428 scopus 로고    scopus 로고
    • Rimonabant: Endocannabinoid inhibition for the metabolic syndrome
    • DOI 10.1111/j.1742-1241.2006.01210.x
    • Wierzbicki AS,. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 2006; 60: 1697-706. (Pubitemid 44742174)
    • (2006) International Journal of Clinical Practice , vol.60 , Issue.12 , pp. 1697-1706
    • Wierzbicki, A.S.1
  • 3
    • 0021813187 scopus 로고
    • Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
    • DOI 10.1007/BF00280883
    • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9. (Pubitemid 15018832)
    • (1985) Diabetologia , vol.28 , Issue.7 , pp. 412-419
    • Matthews, D.R.1    Hosker, J.P.2    Rudenski, A.S.3
  • 4
    • 77956017429 scopus 로고    scopus 로고
    • Rimonabant for prevention of cardiovascular events (CRESCENDO): A randomised, multicentre, placebo-controlled trial
    • Topol EJ, Bousser MG, Fox KA, et al., Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010; 376: 517-23.
    • (2010) Lancet , vol.376 , pp. 517-523
    • Topol, E.J.1    Bousser, M.G.2    Fox, K.A.3
  • 6
    • 0027434883 scopus 로고
    • Benefits and adverse effects of weight loss: Observations from the Framingham study
    • Higgins M, D'Agostino R, Kannel W, Cobb J, Pinsky J,. Benefits and adverse effects of weight loss. Observations from the Framingham Study. Ann Intern Med 1993; 119 (7 Pt 2): 758-63. (Pubitemid 23313703)
    • (1993) Annals of Internal Medicine , vol.119 , Issue.7 , pp. 758-763
    • Higgins, M.1    D'Agostino, R.2    Kannel, W.3    Cobb, J.4
  • 7
    • 79956093046 scopus 로고    scopus 로고
    • Biopsy-proven NASH treatment with rimonabant: A case series
    • Barros F,. Biopsy-proven NASH treatment with rimonabant: a case series. J Hepatol 2009; 50 (Suppl. 1): S355.
    • (2009) J Hepatol , vol.50 , Issue.SUPPL. 1
    • Barros, F.1
  • 8
    • 42949154244 scopus 로고    scopus 로고
    • Diagnosis and Therapy of Nonalcoholic Steatohepatitis
    • DOI 10.1053/j.gastro.2008.02.077, PII S0016508508003508
    • Torres DM, Harrison SA,. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-98. (Pubitemid 351615413)
    • (2008) Gastroenterology , vol.134 , Issue.6 , pp. 1682-1698
    • Torres, D.M.1    Harrison, S.A.2
  • 9
    • 77955286305 scopus 로고    scopus 로고
    • Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity
    • Tam J, Vemuri VK, Liu J, et al., Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120: 2953-66.
    • (2010) J Clin Invest , vol.120 , pp. 2953-2966
    • Tam, J.1    Vemuri, V.K.2    Liu, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.